DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Oppenheimer - 1 McCormick - 1 Argus - 1 Needham - 1 it's - 1 Nelson Peltz - 1 Melius - 1 Horton - 1
Top related locs:
underperform LEN DHI Asia Eaton 4Q23
Top related orgs:
Citi - 2 Olema Pharmaceuticals - 2 Nvidia - 1 JPMorgan - 1 Disney - 1 Boeing - 1 Coca - 1 MTH - 1

Search resuls for: "Olema Pharmaceuticals"


2 mentions found


☆ Here are Tuesday's biggest analyst calls: Nvidia, Meta, Boeing, Eli Lilly, Disney, Coca-Cola, Grindr & more
  + stars: | 2024-04-02 | by ( Michael Bloom | ) www.cnbc.com   time to read: +8 min
Here are Tuesday's biggest calls on Wall Street: Oppenheimer reiterates Nvidia as outperform Oppenheimer said it's sticking with its outperform rating on shares of Nvidia. Citi reiterates Eli Lilly as buy Citi said the biopharma company is "riding the GLP-1 rocket." Citi downgrades Clorox to neutral from buy Citi said that the bullish thesis for the stock has largely played out for now. Citi upgrades Estee Lauder to buy from neutral Citi said it sees a "topline inflection point" for the stock. Barclays upgrades Array Technologies to overweight from equal weight Barclays said it sees share gains for the solar company.
Persons: Oppenheimer, McCormick, Argus, Needham, it's, Nelson Peltz, Melius, Horton, Citi, Eli Lilly, Estee Lauder, ARRY, JMP, Piper Sandler, Piper, Nio, CFRA, Goldman Sachs, Goldman, Blackstone, Petco Organizations: Nvidia, JPMorgan, Disney, Boeing, Citi, Coca, MTH, RBC, GE Vernova, General Electric, Bank of America, Meta, Travel, Barclays, Eaton, MI, Olema Pharmaceuticals, UBS, Bank of, of America Locations: underperform, LEN, DHI, Asia, Eaton, 4Q23
☆ Analysts love these biotech stocks, giving 4 more than 100% upside
  + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com   time to read: +2 min
To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.
Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals
0 next >>
Total: 2